FindTrial
Sign In

Impact of high flow oxygen therapy on outcomes of COVID-19 patients

High Flow Nasal Oxygen Therapy in COVID-19 critically ill patients with acute hypoxemic respiratory failure: An observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/10/028634
Enrollment
100
Registered
2020-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Rajendra Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Confirm COVID- 19 positive patients. Acute Hypoxemic respiratory failure (P/F ratio 25 breaths per minute with respiratory distress

Exclusion criteria

Exclusion criteria: Intubation prior to HFNOT Shock (MAP Requirement of vasopressor infusion

Design outcomes

Secondary

MeasureTime frame
28-day mortality rateTimepoint: 28 day;HFNOT failure rate (i.e , rate of intubation or NIV)Timepoint: At ICU discharge—

Primary

MeasureTime frame
Change in PaO2/FiO2 ratioTimepoint: at 1 hour, 6 hour, 7 days and 14 days—

Countries

India

Contacts

Public ContactDr Mohd Saif Khan

Rajendra Institute of Medical Sciences

drsaif2k2@gmail.com8870561682

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026